Dapagliflozin does not impair microvascular hemorheology in type 2 diabetes mellitus: A multicenter randomized controlled trial (D‐ PATH study)
Journal of Diabetes Investigation · 2026-08 · 17 (8) · 1322-1334
DOI: 10.1111/jdi.70344 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Diabetes Investigation, online erschienen am 22.05.2026. Verfasst von Yuki Nakatani und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes and Endocrinology, Dokkyo Medical University Nikko Medical Center, Tochigi, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Benzhydryl Compounds, Glucosides, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca K.K., Ono Pharmaceutical.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
Sodium–glucose cotransporter 2 inhibitors reduce cardiovascular and renal events beyond glucose lowering, but their hematocrit‐raising effects raise concerns about increased blood viscosity and microvascular impairment. We investigated whether dapagliflozin adversely affects microvascular hemorheology in patients with type 2 diabetes. Materials and Methods In this multicenter, open‐label, randomized controlled trial, 82 adults with type 2 diabetes received dapagliflozin (5 mg/day) or conventional therapy for 16 weeks. The primary endpoint was the change in whole blood passage time (WBPT), measured using a microchannel flow analyzer that simulates precapillary arterioles (7 × 7 μm), with a prespecified noninferiority margin of 6.0 s (15%). Secondary outcomes included apparent microvascular viscosity, adhesive leukocyte count, and oxidative stress markers. Serum erythropoietin (EPO) was evaluated in an ancillary analysis.
Results
WBPT changed minimally in the dapagliflozin group (+1.4 s; 95% CI, 0.0–2.9) and slightly decreased in the control group (−0.6 s; 95% CI, −1.9 to 0.6), yielding a between‐group difference of 2.0 s (95% CI, −0.2 to 3.9), with the upper bound below the prespecified noninferiority margin. Microvascular viscosity, hematocrit‐standardized viscosity, leukocyte adhesion, and oxidative stress markers remained stable in both groups. Dapagliflozin increased hematocrit and EPO, particularly in participants with lower baseline hematocrit, whereas those with hematocrit >45% showed minimal change.
Conclusions
Dapagliflozin did not impair microvascular hemorheology despite modest increases in hematocrit and EPO. These findings support the microvascular safety of dapagliflozin and reinforce its role in cardio–renal risk management in type 2 diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Diabetes and Endocrinology, Dokkyo Medical University Nikko Medical Center, Tochigi, Japan.
- Department of Cardiovascular Medicine and Nephrology, Dokkyo Medical University Nikko Medical Center, Tochigi, Japan.
- Institute for Human Movement and Medical Sciences, Niigata University of Health and Welfare, Niigata, Japan.
- Department of Cardiology, Dokkyo Medical University Nikko Medical Center, Nikko, Japan.
- Department of Cardiovascular Medicine, Nephrology and Neurology, University of the Ryukyus, Okinawa, Japan.
- Yokokawa Clinic, Osaka, Japan.
ORCID-Profile: Yoshimasa Aso
Förderung
- AstraZeneca K.K.
- Ono Pharmaceutical
Zitieren
APA
Nakatani, Y., Banba, N., Ono, S., Turumi, T., Hoshiai, M., Sugiyama, T., Tomoe, T., Tamiya, H., Otani, N., Sugimura, H., Ikemiyagi, H., Ohya, Y., Yokokawa, K., Ueda, S., Aso, Y., Maejima, Y., & Yasu, T. (2026). Dapagliflozin does not impair microvascular hemorheology in type 2 diabetes mellitus: A multicenter randomized controlled trial (D‐ PATH study). Journal of Diabetes Investigation, 17(8), 1322-1334. https://doi.org/10.1111/jdi.70344
Vancouver
Nakatani Y, Banba N, Ono S, Turumi T, Hoshiai M, Sugiyama T, et al. Dapagliflozin does not impair microvascular hemorheology in type 2 diabetes mellitus: A multicenter randomized controlled trial (D‐ PATH study). Journal of Diabetes Investigation. 2026;17(8):1322-1334. doi:10.1111/jdi.70344
BibTeX
@article{Nakatani2026,
author = {Nakatani, Yuki and Banba, Nobuyuki and Ono, Shoya and Turumi, Tomoki and Hoshiai, Megumi and Sugiyama, Takushi and Tomoe, Takashi and Tamiya, Hajime and Otani, Naoyuki and Sugimura, Hiroyuki and Ikemiyagi, Hidekazu and Ohya, Yusuke and Yokokawa, Koji and Ueda, Shinichiro and Aso, Yoshimasa and Maejima, Yasuhiro and Yasu, Takanori},
title = {Dapagliflozin does not impair microvascular hemorheology in type 2 diabetes mellitus: A multicenter randomized controlled trial (D‐ PATH study)},
journal = {Journal of Diabetes Investigation},
year = {2026},
volume = {17},
number = {8},
pages = {1322--1334},
doi = {10.1111/jdi.70344}
}
EUVIMED